title: Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased.
authors.forename: Laurent
authors.initials: L
authors.lastname: Peyrin-Biroulet
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Chevaux
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Bouvier
authors.forename: Fabrice
authors.initials: F
authors.lastname: Carrat
authors.forename: Laurent
authors.initials: L
authors.lastname: Beaugerie
mesh_terms: D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D008545:Melanoma / Q000139:chemically induced*; D015122:Mercaptopurine / Q000009:adverse effects*; D011446:Prospective Studies; D012878:Skin Neoplasms / Q000139:chemically induced*
chemical_list: D007166:Immunosuppressive Agents; D015122:Mercaptopurine